With relocation vote looming, the EMA is openly fretting as cities jockey for attention
The biggest decision that the EMA faces has nothing to do with any drug angling for a European approval or how it’s doing relative to the FDA in providing efficient product reviews. In 10 days the EU will vote on which of the 19 prospective cities will win the right to host the agency in one of the most hotly contested competitions to come out of the UK’s vote in favor of Brexit.
The winner will immediately get the full attention of the leaders of the EMA, who have a list of demands ready to go.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.